Mirna Therapeutics (SYBX) and Its Competitors Financial Comparison
Mirna Therapeutics (NASDAQ: SYBX) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Mirna Therapeutics to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings.
This is a breakdown of recent ratings and target prices for Mirna Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mirna Therapeutics Competitors||114||749||1610||58||2.64|
Mirna Therapeutics presently has a consensus target price of $19.50, indicating a potential upside of 13.57%. As a group, “Biopharmaceuticals” companies have a potential upside of 6.21%. Given Mirna Therapeutics’ higher probable upside, equities research analysts plainly believe Mirna Therapeutics is more favorable than its competitors.
Institutional and Insider Ownership
45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 18.6% of Mirna Therapeutics shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Mirna Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mirna Therapeutics Competitors||-12,981.62%||218.43%||-23.39%|
Volatility & Risk
Mirna Therapeutics has a beta of 4, suggesting that its share price is 300% more volatile than the S&P 500. Comparatively, Mirna Therapeutics’ competitors have a beta of 1.28, suggesting that their average share price is 28% more volatile than the S&P 500.
Valuation & Earnings
This table compares Mirna Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mirna Therapeutics Competitors||$579.30 million||$241.72 million||-6.57|
Mirna Therapeutics’ competitors have higher revenue and earnings than Mirna Therapeutics. Mirna Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Mirna Therapeutics competitors beat Mirna Therapeutics on 7 of the 11 factors compared.
Mirna Therapeutics Company Profile
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.